Alessandra Ambruosi

• Spearhead the development and execution of an innovation pipeline for new excipients and technologies in solid dosage forms, with a focus on poorly soluble drug substances, predictive formulation models and continuous manufacturing.
• Lead the exploration of advanced technologies for the oral delivery of small molecules and peptides, including PROTACs and GLP-1 analogues.
• Oversee a diverse team of 25 professionals across Darmstadt, Mumbai, and Shanghai, ensuring effective collaboration and high-quality product development.

Key Achievements:

• Successfully launched five new products, including an innovative software solution for co-crystal predictions, a specialized polymer designed to enhance the solubility of NCEs, and a novel filler-lubricant blend optimized for continuous manufacturing processes.
• Obtained IVC approval and led the establishment of a new technology center in Mumbai, which successfully opened in February 2025.

• Managed the development and manufacturing of solid formulations for clinical supply in compliance with quality and regulatory standards.
• Acted as CMC leader for a phase I development project.

Key Achievements:

• Made substantial contributions to the launch of Mavenclad by preparing pharmaceutical development documents for health authority submissions.
• Streamlined phase I clinical trial development by successfully formulating and delivering tablets for the 'First Patient In'.